This phase Ib dose-­escalation study evaluated the maximum tolerated dose of WNT974 in combination with encorafenib and cetuximab in patients with BRAF  V600E-mutant metastatic colorectal cancer with RNF43 mutations or RSPO fusions. Here, BRAF is linked to metastatic colorectal cancer.